Camostat Mesilate
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 494.52 |
| Cas No. | 59721-29-8 |
| Formula | C20H22N4O5·CH4O3S |
| Solubility | insoluble in EtOH; ≥160.6 mg/mL in DMSO; ≥32.15 mg/mL in H2O |
| Chemical Name | [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate;methanesulfonic acid |
| SDF | Download SDF |
| Canonical SMILES | CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N.CS(=O)(=O)O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
Rat primary hepatic stellate cells (HSCs) |
|
Reaction Conditions |
500 μmol/L camostat mesilate for 7 d incubation |
|
Applications |
Camostat mesilate (500 μmol/L) inhibited generation of transforming growth factor β (TGF-β) by suppressing plasmin activity and reduced the activity of TGF-β, which blocked in vitro activation of HSCs. |
| Animal experiment:[1] | |
|
Animal models |
Male Wistar rats |
|
Dosage form |
1 ~ 2 mg/g Diet |
|
Applications |
Camostat mesilate (1 ~ 2 mg/g of diet) markedly attenuated an increase in hepatic plasmin and TGF-β levels, HSC activation, and hepatic fibrosis without apparent systemic or local side effects in porcine serum-treated rats. Therefore, camostat mesilate prevented porcine serum-induced rat hepatic fibrosis via a profound reduction in TGF-β generation |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Okuno M, Akita K, Moriwaki H, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology, 2001, 120(7): 1784-1800. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
